Early-onset FAD (familial Alzheimer's disease) is caused by mutations of PS1 (presenilin 1), PS2 (presenilin 2) and APP (amyloid precursor protein). Beyond the effects of PS1 mutations on proteolytic functions of the γ -secretase complex, mutant or deficient PS1 disrupts lysosomal function and Ca 2 + homoeostasis, both of which are considered strong pathogenic factors in FAD. Loss of PS1 function compromises assembly and proton-pumping activity of the vacuolar-ATPase on lysosomes, leading to defective lysosomal acidification and marked impairment of autophagy. Additional dysregulation of cellular Ca 2 + by mutant PS1 in FAD has been ascribed to altered ion channels in the endoplasmic reticulum; however, rich stores of Ca 2 + in lysosomes are also abnormally released in PS1-deficient cells secondary to the lysosomal acidification defect. The resultant rise in cytosolic Ca 2 + activates Ca 2 + -dependent enzymes, contributing substantially to calpain overactivation that is a final common pathway leading to neurofibrillary degeneration in all forms of AD (Alzheimer's disease). In the present review, we discuss the close inter-relationships among deficits of lysosomal function, autophagy and Ca 2 + homoeostasis as a pathogenic process in PS1-related FAD and their relevance to sporadic AD.
Introduction
Autosomal dominant mutations of PS1 (presenilin 1), PS2 (presenilin 2) and APP (amyloid precursor protein) cause EOAD (early-onset Alzheimer's disease). Although EOAD accounts for fewer than 5% of all AD cases, investigation of the three genes responsible has so far provided many of the available clues to suspected pathogenic mechanisms in AD. Mutations of PS1, which are responsible for the vast majority of EOAD cases, can accelerate disease onset to ages as early as the late 20s. In most cases of EOAD, the defining lesions of AD, i.e. NFTs (neurofibrillary tangles) and neuritic plaques, as well as characteristic autophagiclysosomal pathology, resemble the features of later-onset sAD (sporadic AD), although these abnormalities are usually more severe. Notable clinical and neuropathological heterogeneity, however, is sometimes seen among families carrying one of the >120 known PS1 mutations [1] [2] [3] .
PS1, a ubiquitous protein with nine transmembrane domains, exists as a 65 kDa holoprotein in the ER (endoplasmic reticulum). The molecule is cleaved by a furin-like 'presenilinase' to generate a two-chain form [4, 5] , which constitutes the catalytic subunit of the γ -secretase enzyme complex composed of four additional subunits.
Figure 1 An overview of macroautophagy (autophagy)
Multiple signalling pathways and protein modification assemblies initiate the formation of an isolation membrane which is then elongated around the selected substrate or region of cytoplasm (phagophore). The inner and outer bilayers of the isolation membrane close to form a double-membrane-limited autophagosome. Lysosomes fuse with either an autophagosome or an amphisome created by autophagosome-endosome fusion, yielding autolysosomes. The contents of the autolysosome are degraded by hydrolytic enzymes activated within a highly acidic environment by the v-ATPase.
Digestion yields basic metabolites which are released into the cytoplasm to be used for new synthesis or as sources of energy and can also modulate TORC1 (target of rapamycin complex 1) activity and other aspects of autophagy induction [26, 102] . MVB, multivesicular body; PAS, pre-autophagosomal structure. Modified with permission from Nixon, R.A. (2013) The role of autophagy in neurodegenerative disease. Nat. Med. 19, 983-997.
Mutations or deletion of PS1 cause autophagy defects by disrupting v-ATPase assembly and lysosome acidification
Autophagy is a lysosomal degradative pathway for recycling diverse cellular constituents [25, 26] , particularly under conditions of metabolic stress (Figure 1 ). Essential for survival of neurons, autophagy is solely responsible for the cellular turnover of damaged or obsolete organelles and is vital for eliminating misfolded and aggregated proteins, which are poorly degraded by the ubiquitin-proteasome system. Autophagy has been reported to be altered in different neurological disorders, and is considered to be a pathogenic factor in several of these diseases, particularly AD and Parkinson's disease [27] . In AD, disruption of autophagy results in a particularly profuse accumulation of autophagic vacuoles within grossly swollen dystrophic neurites of affected neurons [28] which stems from defects in the lysosomal clearance of autophagy substrates by lysosomes [29, 30] . Growing evidence has linked lysosome system failure during autophagy to multiple pathological outcomes in AD, including accelerated amyloidogenesis, neuritic dystrophy, apoptosis and, possibly, tauopathy [31] [32] [33] [34] .
Mutations of PS1 considerably exacerbate autophagy pathology in EOAD and mouse models of AD [35] , and similar pathology can be induced in neurons and nonneuronal cells by deleting PS1 [20, 36, 37] . Exploring the basis for these effects, Lee et al. [20] demonstrated that the PS1 holoprotein serves as a chaperone in the ER for the v-ATPase (vacuolar ATPase) V0a1 subunit, a six-pass transmembrane protein constituent of the proton pump responsible for full acidification of lysosomes. Binding to the PS1 holoprotein, as this subunit is being translated in the ER, stabilizes the correct folded state and facilitates its glycosylation, believed to be necessary for transit from the ER [20, [38] [39] [40] . In cells lacking PS1, the V0a1 subunit of the v-ATPase is poorly glycosylated and unstable, which prevents adequate delivery to lysosomes and assembly of the multisubunit v-ATPase, leading to greatly diminished levels and activity of the proton pump [41] and resulting in failure to fully acidify lysosomes, which is a requirement for lysosomal protease activation and autophagy [20, 30] . Similar lysosomal acidification defects have now been observed in PS1-knockout blastocysts, PS1-knockout and PS1/2-knockout MEFs (mouse embryonic fibroblasts), PS1-FAD (familial Alzheimer's disease) human fibroblast lines, PS1-knockout neurons and PS1/APP mice [30, 41] . The roles of the V0a1 subunit and of PS1 in lysosome acidification have been confirmed in studies of PS1-ablated cells or mutant PS1 mouse models and other systems [30, [38] [39] [40] 42] , although Coen et al. [43] has proposed that neither of these components is involved in lysosomal pH regulation. The importance of this PS1 chaperone function in AD pathogenesis is underscored by the ability of pharmacological inhibitors of v-ATPase to induce identical AD-related autophagy dysfunction in normal cells and by the complete reversal of this phenotype in PS1-deficient cells by pharmacologically normalizing lysosomal acidification [41] . The connection of PS1 loss of function to Wnt signalling was demonstrated recently in which the loss of PS1 led to an increase in nuclear β-catenin and phosphorylated LRP6 (low-density lipoprotein receptor-related protein 6) due to increased Wnt activity, all of which was attributed to defective acidification of the multivesicular body [38] .
Defective lysosome acidification: an emerging factor in pathogenesis of degenerative diseases
Interestingly, disruptions of normal v-ATPase activity appear to be important for the progression of other diseases. Mutations within the a3 subunit of the v-ATPase cause misfolding and ER retention of this subunit, leading to osteopetrosis, a bone disease that may be accompanied by neurodegeneration [44] . Mice lacking the a3 subunit also have impaired acidification of lysosomes in macrophages [45] . In a rare familial form of Parkinson's disease, the loss of function of ATPase13A2 (Park9), believed to be involved in lysosome acidification, leads to impaired autophagy and neurodegeneration [46] . Mutations in LRRK2 (leucine-rich repeat kinase 2) increase the activity of the protein and lead to late-onset familial Parkinson's disease. Among other pathological effects that have been attributed to this protein kinase, increase in LRRK2 activity leads to pathologically increased autophagy induction and defective lysosomal acidification [47] . Reduced v-ATPase activity and abnormally elevated lysosomal pH due to a deficiency of VMA21, an integral membrane protein required for the assembly of the v-ATPaseV0 complex in the ER, leads to X-linked myopathy, a form of muscle fibre degeneration [48] .
Although lysosomal pH is predominantly maintained through the activity of the v-ATPase, other ion channels localized to the lysosomal membrane are suspected to be important in maintaining or regulating pH shifts during lysosomal proteolysis and may be particularly important when the intraluminal lysosomal environment is disturbed in disease states. The Cl − channel CLC7 has been implicated in fine-tuning lysosomal pH in conjunction with v-ATPase [49] , and other evidence has suggested an involvement of Ca 2 + channels, TRPML1 (transient receptor potential mucolipin 1) and TPC2 (two-pore channel 2), in lysosomal pH regulation [50] [51] [52] . Lysosomal storage disorders exhibit elevated lysosomal pH as a part of the progression of the disease. Elevated lysosomal pH has been detected in several forms of NCL (neuronal ceroid lipofuscinosis), including juvenile NCL (Batten disease) and infantile NCL, leading to altered lysosomal enzyme activity [53] .
Ca
2 + dysregulation in EOAD: the important contribution of defective lysosomal acidification PS1 holoprotein has also been implicated in mediating the γ -secretase-independent effects of AD-causing PS1 mutations (or PS1 deletion) in dysregulating Ca 2 + homoeostasis at several different subcellular levels, including the ER [54] [55] [56] [57] , the MAMs (mitochondria-associated membranes) [58] and lysosomes [43, 59] (Figure 2 ). Ca 2 + homoeostasis in the ER is normally maintained by regulating Ca through the SERCA (sarcoplasmic/endoplasmic reticulum Ca 2 + -ATPase) channel [60] . Although the mechanism(s) is unresolved, loss of function of PS1 leads to ER Ca 2 + dysregulation. Exaggerated Ca 2 + release by IP 3 Rs in response to Ins(1,4,5)P 3 was initially reported in 1994 [61] and confirmed by other groups in different cell types [57, 62, 63] , and more recent studies into the underlying mechanism of the IP 3 R-mediated Ca 2 + release linked the exaggerated release to a gain-of-function mechanism in which mutations in PS1 stimulate IP 3 R gating [64] . The expression of RyRs is also up-regulated in the brains of transgenic mice harbouring PS1 mutations [65] as well as in PC12 cells expressing PS1 mutations and in primary cells from PS1-knockin mice [63] . This increase in RyR channels mediates Ca 2 + release [63, 65] . Additionally, PS1 may act as a passive Ca 2 + leak channel within the ER: mutations within the PS1 holoprotein are proposed to disrupt the leak function, leading ER stores to overfill, thereby overactivating IP 3 Rs and increasing Ca 2 + release [22, 66] . Another group of investigators, however, was unable to observe changes in ER Ca 2 + fill or leak rates in cells lacking presenilin or expressing FAD-linked presenilin mutations [24] , and the basis for the observed differences is not yet resolved. The removal of Ca 2 + from the cytosol back to the ER is controlled by the SERCA pump, but, in cells lacking PS1, PS2 or PS1/2, SERCA activity is diminished, leading to increased cytosolic Ca 2 + . A similar effect has been seen in cells expressing either PS2 or FAD-linked PS2 mutant [67] , although others have observed increased SERCA function leading to the overfilling of ER Ca 2 + stores in cells overexpressing PS2 or AD-linked mutant PS1 [68] . Despite these uncertainties about the precise mechanisms, there is consensus in the field that ER Ca 2 + is dysregulated in response to loss of PS1 function [56, 60] .
Although the ER contains the largest stores of Ca 2 + , with concentrations in the low millimolar range [69] , lysosomes are not far behind with Ca 2 + concentrations in the range 500-600 μM [70] . Recently, efflux of Ca 2 + from lysosomes in PS1/2-knockout MEFs was reported, although the underlying mechanism was not investigated [43] . A subsequent study confirming this phenomenon also revealed reduced levels of the lysosome-associated NAADPdependent Ca 2 + channel TPC2 [59] , although it remains unclear how diminished amounts of a Ca 2 + efflux channel would explain elevated lysosomal Ca 2 + efflux. An earlier study using the lysosomal pH modulators chloroquine and bafilomycin, however, provides an attractive possible basis for Ca 2 + dysregulation in PS1 loss-of-function conditions by linking lysosomal Ca 2 + efflux to changes in lysosomal pH [71] . The possibility that decreased lysosomal Ca 2 + is a direct consequence of elevated lysosomal pH is indeed consistent with our recent findings [41] that raising lysosomal pH in wild-type blastocysts not only reproduces the autophagy defects seen in PS1 mutant or deficient cells, but also induces the abnormal lysosomal Ca 2 + efflux. Importantly, reversing lysosomal pH deficits in PS1-deleted cells rapidly rescues both the lysosomal Ca 2 + abnormalities and the autophagy phenotype. By contrast, reversing the Ca 2 + efflux abnormalities alone corrects neither the acidification defect nor the autophagy deficits in PS1-deleted cells, indicating that lysosomal Ca 2 + dysregulation is a secondary consequence of pH elevation. These studies therefore link two γ -secretaseindependent effects of PS1 loss of function. They imply that vATPase deficiency is the common basis for these deficits and suggest that Ca 2 + efflux from lysosomes may be a significant contributor to the overall defect in cytosolic Ca 2 + elevation seen in PS1-deficient cells.
Altered ER Ca 2 + homoeostasis reflected in a depletion of ER stores leading to elevated cytosolic Ca 2 + is common among several lysosomal storage disorders, and it is possible that the mechanisms are similar to those proposed in the case of PS1 loss of function. Enhanced release of Ca 2 + by the RyRs has been observed in models of Gaucher's disease due to the accumulation of glycosylceramide [72] [73] [74] . The ER Ca 2 + stores are depleted in GM1 gangliosidosis due to the interaction of GM1 with IP 3 Rs [75] , and downregulation of SERCA pumps has been observed in Sandhoff disease [74] and in Neimann-Pick type A disease [76] have also been observed in Neimann-Pick type C disease due to accumulation of sphingosine [78] .
PS1-mediated Ca 2 + dysregulation: a pathway to accelerated calpain-dependent neurofibrillary degeneration in FAD
Altered ER and lysosomal Ca 2 + homoeostasis leads to an increase in cytosolic Ca 2 + levels [54] . One consequence of this is the activation of calpain 1 (μ-calpain) and calpain 2 (m-calpain), proteases that are highly expressed in the central nervous system [79] (Figure 2) . Targets of calpain cleavage include cytoskeletal proteins, signal transduction proteins, synaptic proteins and transcription factors [80] . Abnormally increased activities of both calpain 1 and calpain 2 have been linked to AD [81] [82] [83] , with calpain 1 actions possibly concentrated at synapses [82] and calpain 2 bound to NFTs and more activated within the neurites of neurons at risk of developing NFTs [83] . Calpain overactivation is well established to have many deleterious effects, among them being the pathological activation of CDK5 (cyclin-dependent kinase 5) (through the cleavage of p35 to p25) [84] , ERK1/2 (extracellular-signal-regulated kinase 1/2) [85] , and GSK3β (glycogen synthase kinase 3β) [86] and consequent hyperphosphorylation of tau leading to NFT formation. Calpains can also cleave IP 3 Rs making them constituently active which may further disrupt ER Ca 2 + homoeostasis in PS1-related EOAD [87] . The pathogenic role of calpains in AD is indicated further by the marked depletion in AD patients' brains of calpastatin [88] , the specific endogenous inhibitor of calpains [89, 90] . Moreover, overexpressing calpastatin reduced calpain activity, tau phosphorylation, ERK activation and amyloid plaque load in either of two different mouse models of AD [91, 92] . A synthetic calpain inhibitor, BDA-410, improved spatial memory, fear conditioning and synaptic plasticity associated with increased CREB (cAMP-response-elementbinding protein) phosphorylation in APP/PS1 transgenic mice [93] . Finally, we have recently observed that calpastatin overexpression in the JNPL3 tauopathy mouse model leads to decreased tau phosphorylation, increased lifespan and loss of motor neurons (MK. McBrayer, unpublished work). Because ER and lysosomal Ca 2 + dysregulation is altered in mutant PS1-linked FAD and PS1-knockout cell lines [43, 59] , it is not surprising that we have also found calpains to be robustly activated in PS1-knockout blastocysts and mutant PS1-linked FAD fibroblasts as reflected in marked increase in calpaincleaved spectrin and significantly decreased calpastatin levels (MK. McBrayer, unpublished work).
Conclusions: lysosomal and Ca

+ dysfunction in sAD
Although Ca 2 + dysregulation may be initially driven by presenilin mutations in FAD, additional cellular Ca 2 + derangements are also seen in the more prevalent lateonset forms of AD [94] and probably have a multifactorial origin, including contributions from excitotoxicity, ischaemia and Aβ neurotoxicity [95, 96] . It is tempting to speculate that the notable disruption of lysosomal function in AD [97, 98] may give rise to additional lysosome-related Ca 2 + dysregulation. Interestingly, a further connection has been suggested by Yamashima [95] between calpain activation and lysosomal dysfunction leading to lysosomal membrane rupture, which involves increased calpain-mediated cleavage of carbonylated HSP70.1 (heat-shock protein 70.1). HSP70.1 has roles as both a protein chaperone and stabilizer of lysosomal membrane integrity. Calpain-mediated loss of HSP70.1, coupled with other factors impairing autophagic clearance [98] , are proposed to lead to lysosomal membrane disruption and are likely to diverse downstream pathological events [95] . Calpain activation is observed in patients with sAD, and research indicates that Ca 2 + homoeostasis is also disrupted in sAD [99] [100] [101] . EOAD and sAD probably have different initiation points leading to dysregulated lysosome dysfunction and Ca 2 + dysregulation, but ultimately share pathological outcomes, including calpain overactivation, that should prove to be useful drug targets for AD therapy.
